Zelquistinel for Adults With Major Depression
About this title
Read the official source — NCT03726658Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Understand this study
What did researchers investigate?
Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 226
- Sponsor
- Syndeio Biosciences, Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03726658
- Official title
Show the full official title
A Two-Part, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose (Part A) or Twice Daily Dose (Part B) Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Phoenix · Garden Grove · Atlanta
2 more locations
- Berlin
- Bellevue
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared AGN-241751 and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Syndeio Biosciences, Inc.
Did this study involve medication?
Yes. The study involved medication, including AGN-241751 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
